Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.
The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1989 |
| IPO Date | Apr 1, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Aaron Berg |
Contact Details
Address: Iconic Offices, The Greenway, Block C Ardilaun Court Dublin, 112-114 Ireland | |
| Phone | 353 0 166 99020 |
| Website | amarincorp.com |
Stock Details
| Ticker Symbol | AMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000897448 |
| CUSIP Number | 023111206 |
| ISIN Number | US0231112063 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aaron D. Berg | Chief Executive Officer, President and Director |
| Dr. Steven B. Ketchum Ph.D. | Executive Vice President, President of Research and Development and Chief Scientific Officer |
| Jonathan N. Provoost | Executive Vice President, Chief Legal and Compliance Officer and Secretary |
| Peter Fishman | Vice President, Global Controller, Principal Financial Officer and Principal Accounting Officer |
| Jordan Zwick | Senior Vice President of Corporate Business Development and Investor Relations |
| Laurent Abuaf | President of Europe and Senior Vice President |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs |
| Dr. David Keenan Ph.D. | Executive Vice President of Technical Operations and President of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 7, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| Jul 29, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 8-K | Current Report |
| May 29, 2024 | 8-K | Current Report |
| May 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2024 | 8-K | Current Report |